Teva Pharmaceutical Industries EBITDA 2010-2024 | TEVA

Teva Pharmaceutical Industries annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Teva Pharmaceutical Industries EBITDA for the quarter ending June 30, 2024 was $0.253B, a 171.47% decline year-over-year.
  • Teva Pharmaceutical Industries EBITDA for the twelve months ending June 30, 2024 was $1.957B, a 6212.9% increase year-over-year.
  • Teva Pharmaceutical Industries 2023 annual EBITDA was $1.586B, a 278.4% decline from 2022.
  • Teva Pharmaceutical Industries 2022 annual EBITDA was $-0.889B, a 129.2% decline from 2021.
  • Teva Pharmaceutical Industries 2021 annual EBITDA was $3.045B, a 251.19% decline from 2020.
Teva Pharmaceutical Industries Annual EBITDA
(Millions of US $)
2023 $1,586
2022 $-889
2021 $3,045
2020 $-2,014
2019 $1,278
2018 $3,232
2017 $-15,372
2016 $3,678
2015 $4,660
2014 $6,109
2013 $4,079
2012 $5,172
2011 $4,608
2010 $4,848
2009 $3,313
Teva Pharmaceutical Industries Quarterly EBITDA
(Millions of US $)
2024-06-30 $253
2024-03-31 $55
2023-12-31 $1,010
2023-09-30 $639
2023-06-30 $-354
2023-03-31 $291
2022-12-31 $-646
2022-09-30 $740
2022-06-30 $-592
2022-03-31 $-391
2021-12-31 $375
2021-09-30 $973
2021-06-30 $887
2021-03-31 $810
2020-12-31 $-3,827
2020-09-30 $667
2020-06-30 $554
2020-03-31 $592
2019-12-31 $564
2019-09-30 $331
2019-06-30 $-194
2019-03-31 $577
2018-12-31 $125
2018-09-30 $490
2018-06-30 $585
2018-03-31 $2,032
2017-12-31 $-12,489
2017-09-30 $905
2017-06-30 $-5,163
2017-03-31 $1,375
2016-12-31 $-226
2016-09-30 $932
2016-06-30 $1,383
2016-03-31 $1,589
2015-12-31 $298
2015-09-30 $1,709
2015-06-30 $1,270
2015-03-31 $1,383
2014-12-31 $1,597
2014-09-30 $1,637
2014-06-30 $1,442
2014-03-31 $1,433
2013-12-31 $1,456
2013-09-30 $1,386
2013-06-30 $-82
2013-03-31 $1,319
2012-12-31 $1,982
2012-09-30 $352
2012-06-30 $1,391
2012-03-31 $1,447
2011-12-31 $1,372
2011-09-30 $1,282
2011-06-30 $821
2011-03-31 $1,133
2010-12-31 $1,015
2010-09-30 $1,447
2010-06-30 $1,308
2010-03-31 $1,069
2009-12-31 $512
2009-09-30 $1,104
2009-06-30 $1,011
2009-03-31 $709
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $20.902B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00